Oncology Brothers: Practice-Changing Cancer Discussions SABCS 2024 Highlights - EUROPA, TAILORx, PADMA, EMBER-3 with Dr. Jame Abraham
Jan 15, 2025
Dr. Jame Abraham, a leading medical oncologist specializing in breast cancer at the Cleveland Clinic, shares groundbreaking insights from the SABCS 2024. He discusses the EUROPA trial, revealing the impact of treatment choices for patients over 70. The conversation dives into the TAILORx updates, highlighting anthracycline benefits for high-risk younger patients. Dr. Abraham also explores the PADMA study, affirming the role of CDK4/6 inhibitors, and the promising EMBER-3 results with new oral drugs for advanced cases. A must-listen for cancer treatment innovations!
AI Snips
Chapters
Transcript
Episode notes
Radiation Better Tolerated Than Endocrine In Elders
- EUROPA enrolled patients >70 with T1 N0 ER/PR+ and Ki67 <20% to compare RT alone vs endocrine therapy alone.
- Interim results show RT had better quality of life and fewer treatment-related AEs than endocrine therapy.
Use Shared Decision-Making For Therapy Choice
- Wait for long-term data before broadly omitting endocrine therapy after surgery in older patients.
- Offer RT alone as a reasonable option for patients who cannot tolerate endocrine therapy and use shared decision-making.
High Recurrence Score Favors Anthracyclines
- TAILORx subset analysis shows recurrence score ≥31 patients had improved distant recurrence-free survival with anthracycline-containing regimens.
- Benefit was stronger with larger tumors and higher recurrence scores across age groups.